BPG is committed to discovery and dissemination of knowledge
Featured Articles
4/15/2026 8:59:02 AM | Browse: 15 | Download: 42
 |
Received |
|
2026-01-21 00:57 |
|
Peer-Review Started |
|
2026-01-21 01:44 |
|
First Decision by Editorial Office Director |
|
2026-02-13 07:28 |
|
Return for Revision |
|
2026-02-13 07:28 |
|
Revised |
|
2026-02-26 02:02 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-03-18 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-18 04:15 |
|
Articles in Press |
|
2026-03-18 04:15 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-04-07 02:09 |
|
Publish the Manuscript Online |
|
2026-04-15 07:40 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Dermatology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Comparing lebrikizumab with other systemic immunomodulators for moderate to severe atopic dermatitis: An updated systematic review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chris Alphonse, Muhammad Irfan, Sergio Camilo Torres Céspedes, Chisom Nwanejuafor, Kashfia Nayeem, Elias Hertan, Vrinda Mohan, Haripriya Gupta, Noor Ul Ain Fatima, Luis Adrian Guadarrama Mendoza, Azkah Sardar, Alexander Michael Diaz and Inshal Jawed |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Inshal Jawed, Department of Medicine, Dow University of Health Sciences, Baba-e-urdu Karachi, Karachi 75350, Sindh, Pakistan. inshaljwd@gmail.com |
| Key Words |
Atopic dermatitis; Lebrikizumab; Dupilumab; Tralokinumab; Janus kinase inhibitors; Systematic review; Network meta-analysis; GRADE assessment |
| Core Tip |
An updated systematic review of 28 studies (10847 patients) shows that the efficacy of lebrikizumab, a high-affinity anti-interleukin-13 monoclonal antibody, is equivalent to that of dupilumab and superior to that of tralokinumab in moderate-to-severe atopic dermatitis (AD). The results showed that lebrikizumab performs better than baricitinib and has efficacy comparable to that of most Janus kinase inhibitors. It also has a better safety profile, with no boxed warnings. Data from real-world and extension studies confirm sustained efficacy. Evidence of moderate to high quality suggests lebrikizumab is a reasonable first-line biologic for moderate to severe AD requiring systemic therapy. |
| Publish Date |
2026-04-15 07:40 |
| Citation |
Alphonse C, Irfan M, Céspedes SCT, Nwanejuafor C, Nayeem K, Hertan E, Mohan V, Gupta H, Fatima NUA, Mendoza LAG, Sardar A, Diaz AM, Jawed I. Comparing lebrikizumab with other systemic immunomodulators for moderate to severe atopic dermatitis: An updated systematic review. World J Clin Cases 2026; 14(12): 119171 |
| URL |
https://www.wjgnet.com/2307-8960/full/v14/i12/119171.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v14.i12.119171 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
